

22 May 2024

Investor Webinar

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the **Company**') (ASX: TRI) is pleased to advise that it will host an investor webinar at 11:00 AM AEST (9:00 AM AWST) on Friday, 24 May 2024.

Chief Operating Officer Kai Sun will provide an update on the Company's ongoing Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study, as well as the pathway to US FDA approval for TrivarX's proprietary MEB-001 algorithm, in connection with its stated strategy to commercialise AI-driven solutions to objectively screen for mental health conditions.

The Company will lodge an updated investor presentation today, which will be used during the webinar.

The briefing will be followed by a Q&A session.

Questions can be submitted now to alex@investorstream.com.au or in written form during the webinar.

Anyone wishing to attend the webinar must register using the below link.

Webinar Details

Date and time: 11:00 AM AEST (9:00 AM AWST) on Friday, 24 May 2024

Register via: <https://register.gotowebinar.com/register/2451038356960475488>

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au